Artal Group S.A. Prometheus Biosciences, Inc. Transaction History

Artal Group S.A.

  • $214 Million
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023
BUY
$103.46 - $126.29 $12.6 Million - $15.4 Million
121,756 New
121,756 $13.1 Million

Others Institutions Holding RXDX

# of Institutions
2
Shares Held
29.6K
Call Options Held
0
Put Options Held
0
View Full List

About Prometheus Biosciences, Inc.

RXDX Quotes by TradingView
  • Ticker RXDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,904,100
  • Description
  • Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...
More about RXDX
Track This Portfolio

Track Artal Group S.A. Portfolio

Follow Artal Group S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

News

Stay updated on Artal Group S.A. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email